Market Overview

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of ALNY, ACHC, TRVN, HTHT and SFIX

Share:

NEW YORK, Nov. 18, 2018 (GLOBE NEWSWIRE) -- The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.      

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
Class Period: February 15, 2018 to September 12, 2018
Lead Plaintiff Deadline: November 26, 2018

During the class period, Alnylam Pharmaceuticals, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) Alnylam overstated the efficacy and safety of its Onpattro (patisiran) lipid complex injection; and (2) as a result, Alnylam's public statements were materially false and misleading at all relevant times.

Get additional information about the ALNY lawsuit: http://www.kleinstocklaw.com/pslra-1/alnylam-pharmaceuticals-inc-loss-submission-form?wire=3

Acadia Healthcare Company, Inc. (NASDAQ:ACHC)
Class Period: February 23, 2017 to October 24, 2017
Lead Plaintiff Deadline: December 3, 2018

Throughout the class period, Acadia Healthcare Company, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) the quality of Acadia's U.K. operations did not give the Company a "competitive strength" that would drive future growth and profitability; and (2) defendants had no reasonable basis to believe--and did not in fact believe--their positive statements about the Company's business and financial prospects during the Class Period, including their guidance issued and reaffirmed throughout the Class Period.

Get additional information about the ACHC lawsuit: http://www.kleinstocklaw.com/pslra-1/acadia-healthcare-company-inc-loss-submission-form?wire=3

Trevena, Inc. (NASDAQ:TRVN)
Class Period: May 2, 2016 to October 9, 2018
Lead Plaintiff Deadline: December 10, 2018

The lawsuit alleges that throughout the class period, Trevena, Inc. made materially false and/or misleading statements and/or failed to disclose that: (a) during its meetings with the FDA prior to the start of the Class Period, Trevena had been advised that the FDA did not agree with certain aspects of the design of the Phase III clinical trial of Olinvo, including the proposed dosing, the proposed primary endpoint and the proposed non-inferiority margin for comparing morphine to Olinvo; (b) unless Trevena demonstrated that Olinvo was at least equally effective to morphine in treating post-operative pain in the Phase III clinical trial, the FDA would be unwilling to consider any secondary benefits Olinvo might confer in terms of reduced opioid-related adverse effects ("ORAEs"); (c) the FDA disagreed with how the safety data was being compiled in the Phase II clinical trial; (d) because the FDA did not agree with major tenants of the design of the Phase III clinical trial, it was highly unlikely that the FDA would find the data obtained from that clinical trial sufficient to support Trevena's NDA; (e) because the Phase III clinical trial data being derived would not likely be deemed sufficient to support the NDA for Olinvo, the Company would not be able to market Olinvo as soon as it was leading the market to expect, if ever; and (f) as a result of the foregoing, the Company was not on track to achieve the commercial sales revenues from Olinvo as soon as Defendants had led the market to expect during the Class Period, if ever.

Get additional information about the TRVN lawsuit: http://www.kleinstocklaw.com/pslra-1/trevena-inc-loss-submission-form?wire=3

Huazhu Group Limited (NASDAQ:HTHT)
Class Period: May 14, 2018 to August 28, 2018
Lead Plaintiff Deadline: December 7, 2018

According to the complaint, Huazhu Group Limited allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) the Company lacked adequate security measures to protect customer information; (2) as a result of the foregoing, the Company would be susceptible to increased litigation risk and higher expenses; (3) as a result of the foregoing, the Company's goodwill would potentially suffer, leading to lower revenues; and (4) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially false and/or misleading and/or lacked a reasonable basis.

Get additional information about the HTHT lawsuit: http://www.kleinstocklaw.com/pslra-1/huazhu-group-limited-loss-submission-form?wire=3

Stitch Fix, Inc. (NASDAQ:SFIX)
Class Period: June 8, 2018 to October 1, 2018
Lead Plaintiff Deadline: December 10, 2018

The complaint alleges that throughout the class period Stitch Fix, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) Stitch Fix's active client growth had slowed to a crawl; (2) Stitch Fix had completely shut down its television advertising campaign for 10 of the 13 weeks in fourth quarter 2018, dramatically decreasing the number of new active client additions; and (3) as a result, the Company's current business metrics and financial prospects were not as strong as it had led the market to believe during the Class Period.

Get additional information about the SFIX lawsuit: http://www.kleinstocklaw.com/pslra-1/stitch-fix-inc-loss-submission-form?wire=3

Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. There is no cost or obligation to you. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.

J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
jk@kleinstocklaw.com
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com

Klein NEW logo black transparent.png

View Comments and Join the Discussion!